On Monday, Shares of Home Depot Inc (NYSE:HD), subtract -0.83% and closed at $127.25 in the last trading session. The last trading range of the stock ranges between $127.25 and $128.94. The company’s Market capitalization is $154.96 Billion with the total Outstanding Shares of 1.24 billion. The Home Depot®, the world’s leading home improvement retailer, recently declared the appointment of Jeff Boyd, interim chief executive officer and president of The Priceline Group, Inc. (“Priceline”), to the company’s board of directors. Boyd will serve on the company’s Nominating and Corporate Governance Committee and its Finance Committee. His appointment gives the company 13 directors, 12 of whom are independent. Boyd has served in a number of senior executive positions during his tenure at Priceline, a leading provider of online travel and related services. His planned leadership at Priceline guided the company to grow from a loss in 2002 to a multi-billion dollar profitable business.
Boyd has served as Priceline’s interim CEO and president since April 2016, and has served as its chairman since January 2013. He formerly served in a number of roles of increasing responsibility at Priceline, counting as its president and CEO from November 2002 until December 2013. He was Priceline’s president and Co-CEO from August 2002 to November 2002; its chief operating officer from November 2000 to August 2002; and its executive vice president, general counsel and secretary from January 2000 to October 2000. Before joining Priceline, Boyd was executive vice president, general counsel and secretary of Oxford Health Plans, Inc.
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP), dropped -2.25% and closed at $9.57in the last trading session. The last trading range of the stock ranges between $9.30 and $10.78. The company’s Market capitalization is $470.58 million with the total Outstanding Shares of 43.75 million. During the 52-week trading session the minimum price at which share price traded, registered at $1.01 and reached to max level of $10.78. Corbus Pharmaceuticals Holdings, Inc. (CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic and serious inflammatory and fibrotic diseases, declared recently that Professor Derek Gilroy, Ph.D. presented data on the effects of Resunab in a model of inflammation in healthy volunteers on September 28, 2016. The presentation was made at the 6th European Workshop on Lipid Mediators at Goethe University in Frankfurt am Main, Germany.
Dr. Gilroy, Professor of Experimental Inflammation and Pharmacology at University College of London, presented preliminary data testing effects of Resunab (JBT-101) in a clinical research model of inflammation and its resolution in healthy volunteers. In this established model, inflammation is triggered in healthy individuals by the subcutaneous injection of heat-killed E. coli. Blood flow to the site of inflammation is measured with laser Doppler techniques. Suction blisters are generated over the site of inflammation, and cells and inflammatory mediators are measured in the blister fluid at different times after the injection of E. coli. Subjects receive either oral Resunab or placebo before the procedure.
On the otherhand Maxim Integrated Products Inc. (NASDAQ: MXIM), dropped -3.81% and closed at $38.67 in the last trading session. The last trading range of the stock ranges between $38.62 and $40.35. The company’s Market capitalization is $11.00 Billion with the total Outstanding Shares of 283.64 million. During the 52-week trading session the minimum price at which share price traded, registered at $30.28 and reached to max level of $42.37. Developers of industrial, medical, and IoT products now have an added level of IP and device integrity protection with the DS28C36 DeepCover secure authenticator from Maxim Integrated Products, Inc. (MXIM).
With rampant product counterfeiting, unsafe reuse of medical accessories, and vulnerable network connected sensor nodes, companies recognize the need to integrate strong defenses into their products and systems. The DS28C36 provides a targeted set of asymmetric-key and symmetric-key cryptographic tools in a low cost and compact solution. Asymmetric public-key features are supported with the P256 based elliptic curve cryptography (ECC) algorithm and symmetric secret-key with SHA-256.
The DS28C36 provides two authenticated GPIO pins with optional secure state control and level sensing in addition to an exclusive function to enhance secure download/boot features. The device also integrates sophisticated countermeasures to protect against invasive and noninvasive security attacks. End applications include bi-directional authentication, secure storage of system data (such as system crypto keys), verification of system-critical data, secure boot, and end product usage control. For applications where the host system microcontroller has insufficient computing resources for ECC algorithms or lacks required secure storage for a SHA-256 symmetric key, the DS2476 is a companion co-processor to the DS28C36.